Metabolic and Renal Protective Benefits of Magnesium Supplementation in the Long-Term Management of Patients with Type 2 Diabetes Mellitus  

作　　者：Richard Evers Katholi Marcella Rene Ervin Richard Evers Katholi;Marcella Rene Ervin(Prairie Educational and Research Cooperative, Department of Pharmacology, Southern Illinois School of Medicine, Springfield, USA;Prairie Educational and Research Cooperative, Springfield, USA)

机构地区：[1]Prairie Educational and Research Cooperative, Department of Pharmacology, Southern Illinois School of Medicine, Springfield, USA [2]Prairie Educational and Research Cooperative, Springfield, USA

出　　处：《Journal of Diabetes Mellitus》2023年第2期163-177,共15页糖尿病（英文）

摘　　要：Magnesium deficiency is common in patients with type 2 diabetes mellitus (type 2 DM). When adequate magnesium supplementation is chronically given, patients with type 2 DM appear to have improved glucose control and may have delayed chronic complications. In addition, magnesium supplementation may slow the progression of chronic kidney disease (CKD) and decrease the risk of contrast-induced nephropathy in patients with type 2 DM. Keeping serum magnesium at 2.0 mEq/L or greater appears to accomplish these benefits for patients with type 2 DM. Periodically measuring serum magnesium and estimated glomerular filtration rate (eGFR) allows a physician to adjust the supplemental magnesium dose to accomplish these therapeutic goals while avoiding hypermagnesemia.Magnesium deficiency is common in patients with type 2 diabetes mellitus (type 2 DM). When adequate magnesium supplementation is chronically given, patients with type 2 DM appear to have improved glucose control and may have delayed chronic complications. In addition, magnesium supplementation may slow the progression of chronic kidney disease (CKD) and decrease the risk of contrast-induced nephropathy in patients with type 2 DM. Keeping serum magnesium at 2.0 mEq/L or greater appears to accomplish these benefits for patients with type 2 DM. Periodically measuring serum magnesium and estimated glomerular filtration rate (eGFR) allows a physician to adjust the supplemental magnesium dose to accomplish these therapeutic goals while avoiding hypermagnesemia.

关 键 词：HYPOMAGNESEMIA Contrast-Induced Nephropathy Renal Function SGLT2 Inhibitors Type 2 Diabetes Mellitus 

分 类 号：R69[医药卫生—泌尿科学]